Legends leave Legacys~
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmmmm...
rfid ready - Auto-ID-/RFID-News & Articles - Baggage tracing
www.rfid-live.de/baggage-tracing/
KMA Global Solutions International, Inc. announced that it has delivered its first .... 15.02.2013 - STEAG Energy Services stellt während der Maintenance 2013.
Help! Page has been removed!? (understandable) Cant seem to dig up anything on it? Old?
US Gov National Cancer Center admits Pot kills Cancer Cells
This ought to put an end to any further nonsense about how Pot is Not Medicine
Next time Holder or another Prohibitionist says: "There is no medical use for Marijuana" you will know beyond a shadow of a doubt that they are not only lying, they are deceiving.
http://www.cancer.gov/cancertopics/pdq/cam/cannabis/patient/page2
Have any preclinical (laboratory or animal) studies been conducted using Cannabis or cannabinoids?
Preclinical studies of cannabinoids have investigated the following activities:
Antitumor activity
Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
A study in mice showed that cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.
A laboratory study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.
A laboratory study of cannabidiol in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells.
Stimulating appetite
Many animal studies have shown that delta-9-THC and other cannabinoids stimulate appetite and can increase food intake.
Pain relief
Cannabinoid receptors (molecules that bind cannabinoids) have been studied in the brain, spinal cord, and nerve endings throughout the body to understand their roles in pain relief.
Cannabinoids have been studied for anti-inflammatory effects that may play a role in pain relief.
Have any clinical trials (research studies with people) of Cannabis or cannabinoid use by cancer patients been conducted?
No clinical trials of Cannabis as a treatment for cancer in humans have been found in the CAM on PubMed database maintained by the National Institutes of Health.
Cannabis and cannabinoids have been studied in clinical trials for ways to manage side effects of cancer and cancer therapies, including the following:
Nausea and vomiting
Delta-9-THC taken by mouth: Two cannabinoid drugs approved in the United States are available under the names dronabinol and nabilone. Both dronabinol and nabilone are approved by the Food and Drug Administration (FDA) for the treatment of chemotherapy -related nausea and vomiting in patients who have not responded to standard therapy. Many clinical trials have shown that both dronabinol and nabilone worked as well as or better than some of the weaker FDA-approved drugs to relieve nausea and vomiting. Newer drugs given for chemotherapy-related nausea have not been directly compared with Cannabis or cannabinoids in cancer patients.
Inhaled Cannabis: Three small trials have studied inhaled Cannabis for the treatment of chemotherapy-related nausea and vomiting. Various study methods and chemotherapy agents were used with mixed results. There is not enough information to interpret these findings.
Stimulating appetite
Delta-9-THC taken by mouth: A clinical trial compared delta-9-THC (dronabinol) and a standard drug (megestrol) in patients with advanced cancer and loss of appetite. Results showed that delta-9-THC was not as effective in increasing appetite or weight gain in advanced cancer patients compared with standard therapy. However, a clinical trial of patients with HIV/AIDS and weight loss found that those who took delta-9-THC had increased appetite and stopped losing weight compared with patients who took a placebo.
Inhaled Cannabis: There are no published studies of the effect of inhaled Cannabis on cancer patients with loss of appetite. Studies of healthy people who inhaled Cannabis showed that they consumed more calories, especially high-fat and sweet snacks.
Pain relief
Combining cannabinoids with opioids: In a small study of 21 patients with chronic pain, vaporized Cannabis was added to slow-release oxycodone or morphine and given for five days. Results showed that combining vaporized Cannabis with morphine relieved pain better than morphine alone, while combining vaporized Cannabis with oxycodone did not produce significantly greater pain relief. These findings should be tested in further studies.
Delta-9-THC taken by mouth: Two small clinical trials of oral delta-9-THC showed that it relieved cancer pain. In the first study, patients had good pain relief as well as relief of nausea and vomiting and better appetite. A second study showed that delta-9-THC could be given in doses that gave pain relief comparable to codeine. Higher doses of delta-9-THC were found to be more sedating than codeine. An observational study of nabilone also showed that it relieved cancer pain along with nausea, anxiety, and distress when compared with no treatment. Neither dronabinol nor nabilone is approved by the FDA for pain management.
Whole Cannabis plant extract medicine: A study of a whole-plant extract of Cannabis that contained specific amounts of cannabinoids, which was sprayed under the tongue, found it was effective in patients with advanced cancer whose pain was not relieved by strong opioids alone. This treatment was studied using different doses in a randomized, placebo-controlled clinical trial of cancer patients with chronic pain not controlled by opioids. Patients who received the lower doses of cannabinoid spray showed markedly better pain control and less sleep loss compared with patients who received a placebo. Adverse side effects depended on the dose received. Only patients in the high-dose group had adverse side effects that made the treatment less beneficial than the placebo.
Inhaled Cannabis: A study of inhaled Cannabis in patients with HIV -related peripheral neuropathy found better pain control in the Cannabis group than in the placebo group. To date, no clinical trials have studied cannabinoids in the treatment of chemotherapy-related neuropathy in patients with cancer.
Anxiety and sleep
Inhaled Cannabis: A small case series found that patients who inhaled marijuana had improved mood, improved sense of well-being, and less anxiety.
Whole Cannabis plant extract spray: A trial of a whole-plant extract of Cannabis that contained specific amounts of cannabinoids, which was sprayed under the tongue, found that patients had improved sleep quality.
See all the references to Cannabinoids?
That's why the Feds took out a patent on the use of cannabinoids in 2003. That's right, while raiding legal dispensaries in CA, the feds have held a patent on the use of the main ingredient in Cannabis.
Federal Medical Marijuana Prisoners and Cases
http://www.canorml.org/costs/federal_medical_marijuana_prisoners_and_cases
click to see Pending Cases in California and Elsewhere
This paper at the National Cancer Center should end the debate. But it won't, because too few people will see it and understand the depth of the deception on this herb.
This guy, the King of Hemp
managed to change the world...
And get the last laugh. If only
he could see it now
RIP KoH
The Amazing Story Of How Steve Jobs Took Apple From Near Bankruptcy To Billions In 13 Years
http://www.businessinsider.com/how-steve-jobs-took-apple-from-near-bankruptcy-to-billions-in-13-years-2011-1?op=1
Could CBIS follow in its shadow?
Tis Tis... Why mod the cbis board, which clearly supports the scientific proof that cannabis cures, But yet support novelty products from others??
CBIS has what it takes and you know this!
Cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. Specifically, ?9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) – the two major ingredients of marijuana – have been shown to inhibit tumor growth in a number of animal models of cancer, including glioma.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0054795
The Science on Cannabinoids and Cancer
Summary:
Cannabinoids reduce the spread and growth of cancer cells, including breast cancer, oral cancer, colon cancer, and skin cancer.
Cannabinoids disrupt cancer cells’ metastasis and interrupt their usual cell cycle.
Cannabinoids make cancer cells kill themselves, without affecting healthy cells.
Cannabinoids reduce the spread of tumors and can lead to tumor regression.
Cannabinoids used in cancer treatment have no neurotoxic effects.
In no particular order:
(1) Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
Basic info
Published in: Toxicology Letters (November 2012)
http://www.sciencedirect.com/science/article/pii/S0378427412012854
Daiichi University of Pharmacy (Japan)
Hokuriku University (Japan)
Pennsylvania State University (USA)
Quotes
“Results of the current investigation revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. It is established that activation of the RhoA signaling pathway leads to inhibition of the mobility of various cancer cells, including MDA-MB-231 cells.”
Meaning
Cannabidiolic acid reduces the spread of breast cancer cells, through a pathway that is already known for reducing the spread of other types of cancer cells.
----
(2) Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agent
Basic info
Published in: Best Practice & Research Clinical Endocrinology & Metabolism (Feb 2009)
http://www.sciencedirect.com/science/article/pii/S1521690X09000050
University of Salerno (Italy)
Consiglio Nazionale delle Ricerche (Italy)
Quotes
“[...] predominantly inhibitory effects on tumour growth and migration, angiogenesis, metastasis, and also inflammation have been described. Emerging evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer.”
Meaning
Activating the cannabinoid receptors reduces the spread and growth of tumors, suggesting that cannabinoids could be a new way to treat cancer.
----
(3) Cannabinoids in intestinal inflammation and cancer
Basic info
Published in: Pharmacological Research (August 2009)
http://www.sciencedirect.com/science/article/pii/S1043661809000838
University of Naples Federico II (Italy)
Quotes
“Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids – via direct or indirect activation of CB1 and/or CB2 receptors – exert protective effects in well-established models of intestinal inflammation and colon cancer.”
Meaning
Cannabinoids reduce the spread of cancer cells, disrupt these cells’ metastasis, make cancer cells kill themselves (apoptosis), promote the healing of wounds, and protect the body from inflammation and cancer.
----
(4) Cannabinoids attenuate cancer pain and proliferation in a mouse model
Basic info
Published in: Neuroscience Letters (January 2011)
http://www.sciencedirect.com/science/article/pii/S030439401001493X
University of California, San Francisco (USA)
New York University (USA)
Quotes
“When treated with WIN55,212-2 (non-selective), ACEA (CBr1-selective) or AM1241 (CBr2-selective) agonists in vitro, oral cancer cell proliferation was significantly attenuated in a dose-dependent manner. In vivo, systemic administration (0.013 M) of WIN55,212-2, ACEA, or AM1241 significantly attenuated cancer-induced mechanical allodynia. Tumor growth was also significantly attenuated with systemic AM1241 administration. Our findings suggest a direct role for cannabinoid mechanisms in oral cancer pain and proliferation. The systemic administration of cannabinoid receptor agonists may have important therapeutic implications wherein cannabinoid receptor agonists may reduce morbidity and mortality of oral cancer.”
Meaning
Cannabinoids significantly reduce the spread and growth of oral cancer cells.
----
(5) Endocannabinoid system modulation in cancer biology and therapy
Basic info
Published in: Pharmacological Research (August 2009)
Quotes
“Emerging evidence suggests that agonists of cannabinoid receptors, which share the useful property to discern between tumor cells and their non-transformed counterparts, could represent novel tumor-selective tools to treat cancer in addition to their already exploited use as palliative drugs to treat chemotherapy-induced nausea, pain and anorexia/weight loss in cancer patients. “
Meaning
Cannabinoids can tell the difference between healthy cells and tumor cells.
----
(6) Cannabinoids in the treatment of cancer
Basic info
Published in: Cancer Letters (November 2009)
http://www.sciencedirect.com/science/article/pii/S0304383509002523
University of Otago (New Zealand)
Quotes
“Cannabinoids, the active components of the hemp plant Cannabis sativa, along with their endogenous counterparts and synthetic derivatives, have elicited anti-cancer effects in many different in vitro and in vivomodels of cancer. While the various cannabinoids have been examined in a variety of cancer models, recent studies have focused on the role of cannabinoid receptor agonists (both CB1 and CB2) in the treatment of estrogen receptor-negative breast cancer.”
Meaning
Cannabinoids have been shown to have anti-cancer effects in many different experiments.
----
(7) Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators
Basic info
Published in: Progress in Lipid Research (January 2013)
http://www.sciencedirect.com/science/article/pii/S0163782712000537
University of Aberdeen (UK)
Strathclyde University (UK)
Quotes
“Cannabinoids-endocannabinoids are anti-inflammatory, anti-proliferative, anti-invasive, anti-metastatic and pro-apoptotic in most cancers, in vitro and in vivo in animals. They signal [...] to induce cell cycle arrest, autophagy, apoptosis and tumour inhibition.”
“Evidence in vivo and in vitro shows EPA and DHA can form endocannabinoids that: (i) are ligands for CB1/2 receptors and possibly TRPV-1, (ii) have non-receptor mediated bioactivity, (iii) induce cell cycle arrest, (iii) increase autophagy and apoptosis, and (iv) augment chemotherapeutic actions in vitro.”
Meaning
Cannabinoids not only reduce the spread and growth of cancer cells but also kill cancerous cells. Cannabinoids stop cancer cells from continuing their usual cycle, tell them to eat each other, tell them to kill themselves, and generally reduce the spread of tumors.
----
(8) Cannabis & Cannabinoids
Basic info
Review by the National Institute of Health (USA)
http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page4
Describes and cites scientific evidence.
----
(9) Towards the use of cannabinoids as anti-tumour agents
Basic info
Published in: Nature Reviews Cancer (May 2012)
http://www.ncbi.nlm.nih.gov/pubmed/22555283?dopt=Abstract
Complutense University (Spain)
Quotes
“Various reports have shown that cannabinoids (the active components of marijuana and their derivatives) can reduce tumour growth and progression in animal models of cancer, in addition to their well-known palliative effects on some cancer-associated symptoms.”
Meaning
Cannabinoids can reduce tumor growth.
----
(10) Anti-tumoral action of cannabinoids
Basic info
Published in: Nature Medicine (March 2000)
http://www.nature.com/nm/journal/v6/n3/abs/nm0300_313.html
Complutense University (Spain)
Quotes
“9-Tetrahydrocannabinol, the main active component of marijuana, induces apoptosis of transformed neural cells in culture. Here, we show that intratumoral administration of 9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2. Cannabinoid treatment did not produce any substantial neurotoxic effect in the conditions used.”
Meaning
THC makes cancer cells kill themselves. Cannabinoids led to a considerable regression of tumors in rats, but did not lead to neurotoxic effects.
----
(11) Gliomas / Cancer
Basic info
Review by NORML (USA)
http://norml.org/library/item/gliomascancer
Describes and cites scientific evidence.
----
(12) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
Basic info
Published in: The Journal of Clinical Investigation (January 2003)
http://www.jci.org/articles/view/16116
Complutense University (Spain)
Clemson University (USA)
Quotes
“In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB1/CB2 agonist WIN-55,212-2 or the selective CB2 agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells. This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors (VEGF, placental growth factor, and angiopoietin 2). Abrogation of EGF-R function was also observed in cannabinoid-treated tumors. These results support a new therapeutic approach for the treatment of skin tumors.”
Meaning
Cannabinoids led to the suicide of skin cancer cells, but did not affect healthy skin cells. Cannabinoids considerably reduced the growth of skin cancer, and prevented the tumor from creating new blood vessels.
Its nice to hear something finally!
RIGH CEO finally speaks!
Email from CEO Angel February 7th 2013. Response to rick25.
Hi Richard,
Thanks, as always, for reaching out. I do understand that we've been silent on the PR side, but that's not for any reason in particular. There is progress, just not progress worthy of a PR (yet). There is no reason to push fluff. Here's a basic overview of what's occurring with the company. Feel free to share amidst colleagues. This contains no proprietary or definitive forward-looking statements, nor is it meant to be perceived as such.
- Testing services continue as a revenue source. However, our future expansion plans are where the real revenue is. Testing is (and has alway been) just "step one". Analytical testing is our platform for valuable data collection, which in turn drives BGMT's business strategy.
- BGMT's future expansion plans require additional capital reserves beyond current revenue sources to implement. This was expressed in recent financials as well. Simply, technology is expensive to build. Great technology is very expensive to build. We've accomplished our initial goals of branding and dominance in the marketplace. Now it's time to get larger investment groups involved.
There are two ways to raise capital via a public company... a) on the back of the shareholders through dilution or direct stock sale, OR, b) through private capital raise via company equity (thus minimizing dilution). The company has never once utilized the existing shareholder base as a means to raise capital. This is the type of volatility introduced by the previous RightSmile management that we've looked to avoid creating in the marketplace. Path "B" is our focus, as it benefits all current shareholders. We also have strong preferred stock reserves to implement this. However, this path takes time and is often a moving target. The new laws in CO and WA have greatly assisted our efforts and we continue to push forward.
As I'm sure you know, any investment from current shareholders is only shared among the "trading marketplace". BGMT has never seen one spendable dollar from the shareholder base. BGMT receives no benefit from the publicly traded shares, as neither BGMT nor its principals have ever sold a share.
Once these processes are complete, we move forward with the full audit, and uplisting. A new S1 on the QB is expected to benefit all shareholders.
- I mentioned a year ago about BGMT's plans to enter the mobile health and mobile health device market. This continues to be our next product evolution for the alternative care marketplace. We've identified the technology, and we've identified our knowledge sources (IP). It's a hot market, and a hot product. As I predicted, this is one of the biggest tech buzzes now. It will take about 12 months of development to complete, with a prototype available around roughly the 6 month period. That timer starts once we have the resources aboard that we need to embrace full-fledged R&D. Impressive board members and executive appointments are also pending as we move forward along this tract. Much is in alignment. You will see these as future PRs, bearing that all continues to go to plan.
- We've also recently identified a new product strategy that we expect to bring in a new revenue stream, likely within several months of signed agreements. This involves the production of a new nutraceutical product, specific to the cannabis industry. It is unlike any product that our competitors have released or have spoken about thus far. However, it's too early to tell if we'll even pull the trigger on this. We're in the phase of legal due diligence and intellectual property negotiations. We are truly at a 50/50 stage right now, and the project could be shelved just as easily as it may be adopted. I'm quite particular about what projects we bring on board, and I've passed on various opportunities in the past few months. However, if we do move forward with this, it will be absolutely fantastic. But all public disclosures considered, I am not saying that we will or we won't -- only that BGMT is exploring options. We continue to explore several options to boost shareholder value and ongoing revenues.
FYI -- you can begin to perceive the related emerging strategy with this previously released news:
http://finance.yahoo.com/news/bg-medical-welcomes-naturopathic-doctor-133000391.html
- There is also the issue of the promissory notes related to Baron Capital. Baron and BGMT have benefitted from an amicable relationship thus far. However, we will continue to require flexibility from Baron to continue a positive relationship between the two companies. RightSmile was a bundle of muck when we took it over. Much of this has been cleaned up through 2012. However, as of 2013, there are a few more details to be worked out. These talks are ongoing and I look forward to a suitable resolution for both companies' benefit.
- Lastly, the "name change". There's not much more to say here that I haven't before. The name change is a milestone that is both symbolic and tangible. Symbolically, it represents that every last morsel of "RightSmile" is in the past. Tangibly, it represents a strong signal to the market that we're pressing forward with all resources in hand. In summary, once there is full resolution with past RightSmile actions with Baron, and once BGMT has access to capital resources (and/or a near-term product in play) the name change will occur. The papers are already completed, and are awaiting my signature. I'll sign them when the runway is clear for takeoff. It will mean a great deal to me (and all shareholders) when this occurs. It will also be accompanied with great PR.
I wish you the best, and thanks for your patience.
The BGMT staff continues to work diligently towards a very bright future for the company and its shareholder base.
Warm Regards,
Angel Stanz, CEO
BG Medical Technologies, Inc.
RightSmile, Inc.
angel@bgmedtech.com
direct: (424) 240-9320
=========================
(OTC: RIGH) -- BG Medical is a technology and services provider for the medical cannabis industry, delivering an educational consumer experience through an expanding suite of software and services. BG Medical's flagship brand, BudGenius.com, is a leading online portal providing medicine matching and directory services enabling patients to select and locate the most effective cannabis for their ailments. BG Laboratories provides potency, pesticide, and contaminant analysis reporting for safe medical cannabis use. http://www.budgenius.com
=========================
Show me a biotech that started up with no research and that brings a product to market? You think it just happens over night? Just show me ONE and i'll be happy!
I have realized that, hence the reason why im a major supporter of what CBIS is trying to do here~
Enough with the big pharma crap! The only thing they will do is Pump organic buds full of chemicals! Then when you get a new disease from "their" federally approved medicine, they can make a profit by prescribing a "pill" to fix it!
CBIS is trying to CURE disease! Not put a bandaid on it so they can suck your money out while you die slowly! Corruption at its finest~
Iron ridge is sitting @ .002 plus its a dilution machine! Would be nice to see a breakout~
Very entertaining day here so far~
Cannabis Science, Inc. (CBIS) was another stock seeing increased activity during yesterday's trading session. The company saw shares rise 34.48% to close at $0.094 on volume of nearly 50 million shares traded. The company has seen a 98% rise since announcing it's Corporate Operational Guidance for 2013, highlighting a strategic action plan to "bring to market" innovative, cannabinoid-based, life-saving, anti-cancer drugs. Find out if the stock will continue to rise or if its time for a pull back in our exclusive report at: http://squawkboxstocks.com/report/CBIS
But you said at .04 we wouldnt see .05 again? You also said CBIS was going to trips? And then you said it was filling for ch. 11?? And.....
Hey now! Shorts are great! Expecially when they get squeezed like a zit:)
And the technicals finally got a much needed breather! CBIS trades like a champ!!
Keep slurpin the milk from big pharms teet~ 4 days up and a touch of red and you come to save the day with your amazing investing advice! Everyone BUT you is banking with CBIS! Give it up...
Nice! Filling the gap~
Great day here$$$
Yup, just like last week you said the 5's were gone and never coming back..
Maybe, we shall see~
"The company reported previous year revenue of 8.28 K. Net Loss for the year was (1.23 M) with profit before overhead, payroll, taxes, and interest of 17.77 K."
.
What ever happened with Otherside Health Management?
You still watching "Lilbirdy"?
Riding "on the house" shares now~ As good as the T/A looks, im tired of turning blue holding my breath for the next update.. Glad to see the company making forward progress! Now the question is, will they keep it going and utilize the blurp of investor belief? Or kill the little bit of momo by going silent again??
Moving Average Indictors
15 Day Trend bullish
45 Day Trend bullish
100 Day Trend bullish
Momentum Indicators
10 Day Trend bullish
40 Day Trend bullish
100 Day Trend bullish
Stochastics neutral
RSI bearish
MACD bullish
WOOT!
So who investigates the SEC?
Only a sheep following the herd would believe a goverment entity cant screw up~
Another Fumble by the S.E.C. on Fraud
http://www.nytimes.com/2012/11/17/business/another-fumble-by-the-sec.html?pagewanted=all&_r=0
Column: The SEC fumbles a crucial post-crisis battle
http://www.reuters.com/article/2012/08/23/us-column-sec-idUSBRE87M0NQ20120823
When Will the S.E.C. Ever Admit They Made a Mistake?
http://executivesuite.blogs.nytimes.com/2009/11/05/when-will-the-sec-ever-admit-they-made-a-mistake/
The SEC admits to making some mistakes in its fraud charges to Zeek Rewards
http://executivesuite.blogs.nytimes.com/2009/11/05/when-will-the-sec-ever-admit-they-made-a-mistake/
SEC Wrong Again, Naturally:
http://www.questia.com/library/1G1-162234884/sec-wrong-again-naturally-the-sec-s-proposed-rule
Hey, its better than how they have performed in their past! Usually when they say they are gunna do something, thats the last you hear about it!
Aequitas Energy, Inc., a licensed Connecticut electric supplier, officially launched their retail electric service in Connecticut January 25, 2013.
"Due in part to Aequitas Energy's highly competitive generation rate per kWh, the immediate response during the first week has been greater than the company ANTICIPATED. "
Good! It just makes sense to switch over~
Noob!! At Last, VPER finally completed something:) Maybe their starting to mature, and we can look forward to more things completed; To many for me to even remember~
Should give us a nice "pop"
http://www.aequitasenergy.com/
My bad, didnt mean too! Was ment for the board~
Why is it that the marijuana stocks have people jumping into other mmj boards, which they are CLEARLY NOT invested in, just to take a shizz on it because the PPS isnt sky rocketing!?!? It makes no sense to me? Immature to say the least! Im just happy to see the WHOLE SECTOR rise, weather it be slow and steady, or fast and "top heavy"
CBIS will have its day!
Boooom!!! KMAGNUM!!! Nice close~
Hmmm.. Thats rather interesting!
Cannabis Science Inc is currently traded for 0.05 . This company has historical hype elasticity of 0.31 and average elasticity to hype of competition of 0.27. Cannabis Science Inc is projected to increase in value after the next headline with price going to jump to 0.06605508474576272. The average volatility of media hype impact on the company stock price is about 358.67%. The price appreciation on the next news is estimated to be 32.11% where as daily expected return is currently at 0.18%. The volatility of related hype on Cannabis is about 415.3% with expected price after next announcement by competition of 0.32. The company currently holds 1.05 M in liabilities. Cannabis Science Inc has Current Ratio of 0.11 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due. Given investment horizon of 30 days, the next projected press release will be in about 6 days.
Pssst.... Thats from 2003! So yet again, your statement is incorrect!
Quote:
"On a regular basis findings are made only to be negated a year or two later."
Cannabinoids as antioxidants and neuroprotectants
Abstract
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1##
Care to explain then why the U.S Government has a patent on it then?
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6630507.PN.&OS=PN/6630507&RS=PN/6630507
And not just your biased opinion this time!